Genmab A/S (GMAB) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Momentum 1.4/10 is below the 5.0 floor at $26.59 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 7 days (event risk); Weak growth.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma... Read more
Sell if holding. Momentum 1.4/10 is below the 5.0 floor at $26.59 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 7 days (event risk); Weak growth. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Score 5.2/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.4/10 is below the 5.0 floor at $26.59 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 7 days (event risk); Weak growth. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Prior stop was $24.95. Score 5.2/10, moderate confidence.
Take-profit target: $32.78 (+23.8% upside). Prior stop was $24.95. Stop-loss: $24.95.
Earnings in 7 days (event risk); Weak growth; Negative momentum.
Genmab A/S trades at a P/E of 17.0 (forward 15.2). TrendMatrix value score: 7.3/10. Verdict: Sell.
27 analysts cover GMAB with a consensus score of 3.7/5. Average price target: $38.
What does Genmab A/S do?Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of...
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.